Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

Leukemia. 2017 Apr;31(4):997-1000. doi: 10.1038/leu.2017.5. Epub 2017 Jan 11.
No abstract available

Publication types

  • Clinical Trial, Phase II

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bortezomib / therapeutic use*
  • Chemokine CXCL12
  • Dexamethasone / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / metabolism
  • Oligoribonucleotides / antagonists & inhibitors*
  • Oligoribonucleotides / therapeutic use*
  • Proteasome Endopeptidase Complex / metabolism

Substances

  • CXCL12 protein, human
  • Chemokine CXCL12
  • Oligoribonucleotides
  • Bortezomib
  • Dexamethasone
  • Proteasome Endopeptidase Complex